Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BOR15001L7
- Development stage
- Phase 2
- Lead developer
- Laboratoire Boreaderme
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
BOR15001L7 is a natural product under development as a topical treatment for cold sores (herpes labialis), specifically in patients with recurrent herpes labialis. It is being evaluated in clinical trials to determine its safety and efficacy compared to docosanol 10% cream, with the primary goal of demonstrating non-inferiority based on healing time. The drug is developed by Laboratoire Boreaderme and has been tested in open-label Phase 2 studies. Its mechanism of action has not been explicitly described in available sources, but it is positioned as an alternative topical therapy for managing symptoms such as pain, tingling, itching, and burning associated with herpes labialis.
Beyond the preview
Go deeper on BOR15001L7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BOR15001L7.